Precision Oncology Gains From Real‑Time Biochemical Data

At a press briefing in New Delhi, Dr. Shyam Agrawal, chair of the medical oncology division at Sir Ganga Ram Hospital, described how real‑time biochemical observation can illuminate how cancer cells react to candidate therapies. The method accelerates detection of fine‑grained metabolic changes, aiding the rapid pinpointing of effective treatment options during pre‑clinical work.

He stressed that pairing comprehensive genomic profiling with minimal residual disease detection equips precision oncology with tools to tailor personalized, targeted cancer regimens for patients.

Parimita Mishra, founder‑CEO of the San‑Francisco biotech firm Precigenetics, explained that her platform continuously records live biochemical signals from cells, avoiding the conventional need to stain, fix, or destroy samples. This live‑monitoring approach uncovers data previously inaccessible to researchers.

Mishra noted that the ramifications extend into immunology, neuroscience, rare disease investigation, and regenerative medicine, as scientists can shift from discrete endpoint readings to a longitudinal study of cellular behavior.

Cancer drug discovery remains a formidable hurdle in pharma, with many experimental agents failing before reaching patients, often due to lab models that cannot fully capture the dynamic nature of living cells.

According to the International Agency for Research on Cancer, India reported roughly 1.4 million new cancer cases in 2022, and national medical research councils predict a continual rise in cancer incidence over the next ten years.